Ischaemic optic neuropathy (ION) is a rare but vision-threatening complication recently linked to GLP-1 receptor agonists, particularly semaglutide. Using over 30 million reports from the FDA Adverse ...

As an increasing number of patients come forward with claims that their vision has been permanently impacted by weight loss jabs, eye experts have issued a vital statistical warni ...

Nonarteritic, anterior ischemic optic neuropathy is the most common form of ischemic optic neuropathy. 3,4 Typical presentation includes acute, unilateral, and painless loss of central and/or ...

A new study published in British Journal of Ophthalmology has compared the risk of ischemic optic neuropathy (ION) among people who take semaglutide medication. As part of the study, the scientists ...

An increased risk for ischemic optic neuropathy may be associated with formulation- and dose-dependent GLP-1 receptor agonist use.

A new study found that users of Wegovy have nearly five times the risk of ischemic optic neuropathy (ION), compared to ...

Researchers found that the odds of developing an eye condition that leads to vision loss were about 5 times higher among ...

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide was associated with an increased risk for nonarteritic anterior ischemic optic neuropathy — a form ...

Please provide your email address to receive an email when new articles are posted on . The deep learning system demonstrated an AUC of 0.97, a sensitivity of 91.1%, a specificity of 93.4% and an ...